ALIMERA SCIENCES, INC. (NASDAQ:ALIM) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.
Inc. (the Company) held on June 22, 2017 (the Annual Meeting),
the following proposals were submitted to the stockholders of the
Company:
|
Proposal 1:
|
The election of three directors to serve as Class I
directors for a term of three years until the 2020 annual meeting of stockholders. |
|
Proposal 2:
|
The ratification of the selection of Grant Thornton LLP
as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2017. |
|
Proposal 3:
|
The approval on an advisory, non-binding basis of the
compensation of the Companys named executive officers. |
|
Proposal 4:
|
The advisory, non-binding vote on the frequency of
stockholder advisory, non-binding votes on the compensation of our named executive officers. |
Companys definitive proxy statement on Schedule 14A (Amendment
No. 1) filed with the Securities and Exchange Commission on May
3, 2017 (the Proxy Statement). Of the 64,862,904 shares of the
Companys common stock, including 8,135,593 shares of common stock
underlying the Companys outstanding Series A Preferred Stock
(based on a deemed conversion price of $2.95 per share), entitled
to vote at the Annual Meeting, 51,167,771 shares, or
approximately 78.89%, were represented at the meeting in person
or by proxy, constituting a quorum. The number of votes cast for,
against or withheld, as well as abstentions and broker non-votes,
if applicable, in respect of each such matter is set forth below:
|
Proposal 1:
|
Election of Directors.
|
to serve as Class I directors until the 2020 annual meeting of
stockholders. The votes regarding the election of directors were
as follows:
|
Director
|
Votes For
|
Votes Withheld
|
Broker Non-Votes
|
|
James R. Largent
|
33,603,751
|
487,037
|
17,076,983
|
|
C. Daniel Myers
|
33,296,651
|
794,137
|
17,076,983
|
|
Calvin W. Roberts, M.D.
|
33,605,751
|
485,037
|
17,076,983
|
|
Proposal 2:
|
Ratification of Selection of Grant Thornton LLP.
|
Thornton LLP as the Companys independent registered public
accounting firm for the fiscal year ending December 31, 2017. The
votes regarding this proposal were as follows:
|
Votes For
|
Votes Against
|
Votes Abstaining
|
Broker Non-Votes
|
|
50,221,866
|
738,940
|
206,965
|
|
Proposal 3:
|
Compensation of Named Executive Officers.
|
basis the compensation paid to the Companys named executive
officers, as disclosed in the Proxy Statement. The votes
regarding this proposal were as follows:
|
Votes For
|
Votes Against
|
Votes Abstaining
|
Broker Non-Votes
|
|
32,590,385
|
1,277,338
|
223,065
|
17,076,983
|
|
Proposal 4:
|
The Frequency of a Vote on Executive Compensation.
|
the option of every 1 year for the frequency of holding an
advisory, non-binding vote on executive compensation. The votes
regarding this proposal were as follows:
|
Votes for 1 Year
|
Votes for 2 Years
|
Votes for 3 Years
|
Votes Abstaining
|
Broker Non-Votes
|
|
33,038,435
|
414,327
|
412,044
|
225,982
|
17,076,983
|
Directors as set forth in the Proxy Statement, and based on the
voting results for this Proposal 4, the Companys Board of
Directors determined that an advisory vote to approve the
compensation of the Companys named executive officers will be
conducted on an annual basis. The Companys Board of Directors
will reevaluate this determination after the next stockholder
advisory vote on this matter is held.
About ALIMERA SCIENCES, INC. (NASDAQ:ALIM)
Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company’s product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.
